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ABSTRACT 
Immune protection from infectious diseases and cancer is mediated by individual T-
cells of different clonal origin. Their functions are tightly regulated but not yet fully 
characterized. Understanding the contribution of each T-cell will improve the 
prediction of immune protection based on laboratory assessment of T-cell responses. 
Here we developed novel techniques for simultaneous molecular and functional 
assessment of single CD8 T-cells directly ex vivo. We studied two groups of 
melanoma patients, after vaccination with two closely related tumor antigenic 
peptides. Vaccination induced T-cells with strong memory and effector functions, as 
found in virtually all T-cells of the first patient group, and fractions of T-cells in the 
second group. Interestingly, high functionality was not restricted to dominant 
clonotypes. Rather, dominant and non-dominant clonotypes acquired equal 
functional competence. In parallel, this was also found for EBV- and CMV-specific 
T-cells, Thus, the non-dominant clonotypes may contribute similarly to immunity as 
their dominant counterparts. 
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INTRODUCTION 
Naturally acquired self-antigen (tumor)-specific T-cell responses can be detected in 
most cancer patients with advanced disease, however, they often fail to control or 
eliminate the disease, in contrast to many virus-specific CD8 T-cell responses (1, 2). 
This likely reflects the impact of both central and peripheral tolerance in shaping self 
antigen-specific T-cell repertoires. Vaccination against cancer aims to generate 
and/or boost effective type 1 immune responses (Th1 and CD8 T-cell activation) to 
destroy tumor cells and prevent tumor progression. These goals are similar to those 
set for vaccines designed to treat chronic viral diseases. There is a great need to 
characterize and determine the biological similarities and differences between 
protective (e.g. EBV- and CMV-specific) and non-protective (e.g. tumor-specific) T-
cell responses.  
Only limited data is available regarding T-cell clonotype dynamics in therapeutic 
vaccine settings. Yet, clonotypic analyses provide great insight, mostly because T-
cell clonotypes can be followed in a straightforward manner at any time and body 
location using the TCR as a clonotypic marker (3). For example, combined ex vivo 
analysis of T-cell differentiation and clonality allowed the identification of a naturally 
primed T-cell clone in a melanoma patient (4). The progeny of this clone dominated 
the CD8 T-cell response to the tumor antigen Melan-AMART-1, similarly to the clonal 
expansions observed in virus-specific T-cell responses (5-7). However, in several 
patients and healthy individuals, one can also find large numbers of low/non-
dominant T-cell clonotypes among tumor-specific (8) and virus-specific (6) CD8 T-
cells. Remarkably, not only the dominant, but also the subdominant virus-specific 
clonotypes were maintained stably over years, keeping the TCR repertoire 
composition constant (6). These observations raise the question whether dominant T-
 5 
    
cell clonotypes alone are sufficient, or whether low/non-dominant clonotypes are also 
functionally competent and may contribute to immune protection. 
Historically, research has mostly focused on dominant T-cell clonotypes, whereas the 
in vivo functions of non-dominant clonotypes remain poorly characterized, likely 
because of technical limitations. Therefore, we developed new methods suitable for 
the ex vivo functional assessment of individual T-cells, combined with clonotypic 
characterization. With this strategy, we analyzed clonal responses of tumor antigen-
specific T-cells from melanoma patients, in parallel to protective EBV- and CMV-
specific T-cells. The melanoma patients had received potent low dose synthetic 
vaccines composed of Melan-A26-35 peptide, CpG-ODN 7909 and Incomplete 
Freund’s Adjuvant (IFA). This vaccine consistently induced strong T-cell responses 
that were easily detectable by direct ex vivo analysis (9), not only when the Melan-A 
A27L analog peptide (optimized for enhanced HLA-A*0201 binding) was used for 
vaccination, but also with the weakly antigenic native peptide (10). We have 
previously shown that the native peptide induced T-cell responses with increased 
capacity to recognize tumor cells and increased overall T-cell functionality (10). 
Here, we demonstrate that this superior tumor reactivity was associated with 
enhanced effector cell activation of nearly all individual T-cells. Importantly, these 
properties were found in both dominant and non-dominant tumor antigen-specific T-
cell clonotypes. Our data reveal that T-cell functions are determined primarily by the 
antigen used for vaccination and the stage of T-cell differentiation, but are similar in 
dominant and non-dominant clonotypes participating in a CD8 T-cell response. 
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RESULTS 
Strong expansion and differentiation of tumor antigen-specific CD8 T-cells 
following peptide vaccination. Fifteen HLA-A2+ patients with advanced metastatic 
melanoma received monthly vaccinations consisting of either the native Melan-A 
unmodified peptide (EAAGIGILTV, i.e. “EAA”) or the analog Melan-A A27L 
modified heteroclitic peptide (ELAGIGILTV, i.e. “ELA”), combined with CpG-ODN 
7909 and emulsified in IFA (Table S1). Using fluorescent HLA-A2/peptide 
multimers for ex vivo analysis, high frequencies of Melan-A specific CD8 T 
lymphocytes were detected in all patients, and strongly increased as compared to 
before vaccination (defined as time 0; Fig. 1A). We found progressive accumulation 
of late-differentiated effector-memory EM28- Melan-A-specific T-cells (defined 
thereafter as “effector-like” cells), which appeared early in some patients and later in 
others, independent of whether patients received native or analog peptide. The 
established T-cells were maintained over extended periods of time while patients 
continuously received monthly booster vaccinations. 
 
Vaccination-induced T-cell responses are composed of dominant and non-
dominant clonotypes. We characterized in depth the ex vivo TCR repertoire 
diversity resulting from clonal selection of tumor-reactive T-cells in patients 
vaccinated either with the native (EAA; n = 5) or the analog (ELA; n = 10) Melan-A 
peptide (Fig. 1A), as described previously (4). Primed effector-memory EM28+ cells 
(also defined as early-differentiated cells) displayed large polyclonal TCR repertoires 
with a diverse usage of the 22 different BV families studied, and high variability in 
CDR3 size. However, 12 of the 15 patients showed progressive restrictions in TCR 
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BV/CDR3 diversity from EM28+ to EM28- T-cell subsets (Fig. 1B), which was 
accompanied by preferential expansion of several tumor antigen-specific co-
dominant clonotypes of intermediate (low) to high frequencies (Fig. 1C), irrespective 
of whether native or analog peptide was used for vaccination. These clonotypes made 
up in average around 55% of the late-differentiated EM28-“effector-like” subset, but 
only 25% of the early-differentiated EM28+ “effector-memory” T-cells. Our data 
revealed the establishment of relatively few (between 7 to 15) co-dominant tumor-
specific T-cell clonotypes that were highly specific for each patient as defined by 
their private TCR BV CDR3β signatures (Fig. S1A). Importantly, both subsets also 
contained non-dominant T-cell clonotypes, but these were more frequent in EM28+ 
than in EM28- T-cells.  
Altogether, these findings show that similarly to protective virus-specific responses 
(6), vaccination-induced tumor-specific T-cell responses are composed of dominant 
and non-dominant clonotypes (Fig. 1C). Moreover, clonotype selection and 
expansion of tumor antigen-specific T-cells along cell differentiation resembled 
closely those observed in anti-EBV responses (6). These data were obtained 
following cell sorting with multimers bearing the analog peptide. Similar results were 
obtained with multimers bearing the native peptide (Fig. S1B), thus indicating that 
the two multimers efficiently bound to all Melan-A-specific T-cells with similar fine 
specificity to analog or native peptide, in line with our previous report (10). 
 
Enhanced expression of multiple effector mediators by native peptide 
vaccination-induced T-cells, closely resembling highly differentiated CMV-
specific T-cells. To qualitatively assess the effect of native versus analog peptide 
vaccination, we developed techniques for combined ex vivo analysis of molecular and 
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functional properties at the single-cell level, using a modified RT-PCR protocol, 
enabling the detection of specific cDNAs after global amplification of expressed 
mRNAs from individual sorted T-cells (Fig. 2 and Fig. S2A). We found that most 
early-differentiated EM28+ T-cells issued from patients vaccinated with the 
analog/ELA peptide contained low detectable levels of mRNA coding for effector 
mediators such as IFN-γ, perforin, granzyme B and C-type killer cell lectin-like 
receptor CD94, while expressing measurable levels of mRNA coding for the 
costimulatory molecule CD27 and the cytokine receptor IL-7Rα (CD127). Increased 
expression of effector mediators was observed in late-differentiated EM28- T-cells 
after analog peptide vaccination, and was concomitant with down-regulation of 
costimulatory and cytokine receptors (Fig. 2A and 2B). EBV-specific T-cells also 
presented distinct mRNA expression patterns along cellular differentiation, but 
globally these cells remained less differentiated than tumor- or CMV-specific T-cells, 
in agreement with our recent report (6). A remarkable finding was that tumor antigen-
specific T-cells generated following native/EAA peptide vaccination exhibited 
similar detectable levels of effector mediators than those observed in CMV-specific 
T-cells. Remarkably, such expression patterns were already found within the EM28+ 
compartment, despite the co-expression of early-differentiated CD27 and IL-7Rα 
gene transcripts (Fig. 2A and 2B). These cells also showed more poly-functional 
expression profiles compared with the corresponding EM28+ T-cells specific for 
ELA and EBV epitopes (Fig. S2B). 
A hierarchical clustering performed on a total of 529 single-cell samples identified 5 
distinct clusters based on the differential co-expression patterns of the 6 studied genes 
(Fig. 2C). The Heat-map analysis further allowed determining the repartition of these 
clusters within the single-cell samples of each T-cell subset. Strikingly, it revealed 
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that the early-differentiated EM28+ T-cells induced by the native/EAA peptide were 
comprised within the second group formed by the late-differentiated EM28-/EMRA 
“effector-like” ELA-, EAA-, and CMV-specific T-cells. 
The mRNA content correlated with protein expression of CD27, IL-7Rα, IFN-γ, 
perforin and granzyme B, as confirmed by extended ex vivo multi-parameter flow 
cytometry analyses of T-cells from fifteen vaccinated melanoma patients as well as 
seven healthy individuals with persistent herpes virus infections (Fig. 3; Fig. S3). Of 
note, we observed differences in mRNA and protein expression by specific T-cells 
from the same subset that may reflect biological variations among different 
individuals. The expression of CD57, a marker of cellular differentiation, perforin 
and granzyme B were found to be up-regulated even in the early-differentiated 
EM28+ T-cell subset in patients after native peptide vaccination (Fig. 3). Production 
of IFN-γ and up-regulation of LAMP-1 (CD107a) by tumor-specific T-cells showed a 
tendency to increased effector properties after vaccination with native peptide (Fig. 
S3). Altogether, our results indicate that vaccination with the native but not analog 
tumor antigen resulted in enhanced activation and poly-functionality in vivo of 
virtually all specific CD8 T-cells, independently of CD28, CD27 and IL-7Rα co-
expression, and resembling highly differentiated CMV-specific responses. 
 
Both T-cell differentiation and the peptide used for vaccination determine the 
functional profile of individual T-cell clonotypes. The powerful single-cell based 
approach allowed for the first time to analyze in vivo gene expression of (multiple 
representatives of) individual T-cell clonotypes. By this strategy, we compared 
clonotype performance after vaccination with analog versus native peptide based on 
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their frequencies. The functional profiles of dominant T-cell clonotypes (Fig. 4A) 
largely overlapped with those of the corresponding early- or late-differentiated 
subset, respectively (Fig. S2B). For instance, the dominant EM28+ clonotypes from 
patient LAU 618/ELA were less poly-functional and shared the gene expression 
profile found in early-differentiated EM28+ subsets from analog peptide vaccinated 
patients. Conversely, the profiles of the dominant native peptide vaccination-induced 
clonotypes from patient LAU 1013 were highly poly-functional, and corresponded to 
the overall gene expression profiles found within respective EM28+ and EM28- 
subsets. Gene expression signatures of non-dominant tumor-specific T-cells (Fig. 4B) 
also correlated tightly with the subset of origin (e.g. EM28+ or EM28-) and the type 
of peptide used for vaccination (e.g. native or analog peptide). Similar observations 
were made for the dominant and non-dominant clonotypes found in EBV- and CMV-
specific immune responses. In summary, the functional profiles of dominant and non-
dominant T-cell clonotypes were primarily determined by antigen and differentiation 
stage, and not by their degree of prevalence. 
 
Efficient target cell killing by T-cells of both dominant and non-dominant 
clonotypes from patients vaccinated with native peptide. We assessed the ability 
of native and analog peptide vaccination-induced tumor-specific T-cells to recognize 
and kill tumor cells (Fig. 5). As expected, most T-cell clones derived from the late-
differentiated “effector-like” EM28- subset were able to kill the Melan-A-expressing 
tumor cell line Me290, irrespectively of the peptide used for vaccination. However, 
T-cell clones derived from the early-differentiated EM28+ subset following analog 
peptide vaccination were often deficient in cytotoxic function. In contrast, a large 
majority of T-cell clones derived from the same EM28+ subset from patients 
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vaccinated with the native peptide efficiently killed the Me290 cell line. Strikingly, 
this occurred regardless of their clonal prevalence (e.g. dominant or non-dominant 
frequencies; Fig. 5B). The results obtained by such analyses using in vitro generated 
clones are in full agreement with the ex vivo gene (Fig. 2) and protein (Fig. 3) 
expression patterns, thus allowing us to draw conclusions with respect to the in vivo 
status of T-cells. Furthermore, we have previously demonstrated that these T-cell 
clones maintained their specific killing properties despite several weeks of in vitro 
culture (11). Indeed, high and low cytotoxic activity correlated well with high and 
low in vitro and in vivo expression of granzyme B and perforin, respectively (11). 
Collectively, these data show differential cytotoxicity of analog peptide-generated T-
cell clones depending on the in vivo differentiation stage. In contrast to analog 
peptide vaccination, strong cytolytic activity was observed after vaccination with the 
native peptide, regardless of the type of subset (i.e. clones isolated from EM28+ or 
EM28-). Similar efficient target cell killing was observed between dominant and non-
dominant T-cell clonotypes in cytotoxic assays against HLA-A2pos T2 cells pulsed 
with graded peptide concentration (Fig. S4). Our findings reveal a surprising 
functional competence not only of the frequent clonotypes, but also of the rare 
clonotypes among epitope-specific T-cell populations. 
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DISCUSSION 
T-cells from peptide vaccinated melanoma patients provide an ideal opportunity to 
assess possible effects of small antigenic differences in defined therapeutic vaccines 
on memory and effector cell functions, stage of differentiation, and clonotype 
selection. Here, we demonstrate that vaccination with native peptide induced 
functional T-cells in nearly all dominant and low/non-dominant clonotypes. In 
contrast, many T-cells remained poorly functional after vaccination with analog 
peptide, despite similar clonotype-dependent differentiation. The present study shows 
that single-cell analysis provides reliable quantification of individual cells expressing 
particular genes, as confirmed by protein expression analyses. Moreover, our strategy 
was highly sensitive to identify tumor-reactive T-cell clonotypes and to assess their 
frequencies. Finally, our results from these direct ex vivo analyses were in excellent 
agreement with the data obtained with large numbers of T-cell clones generated in 
vitro (6). An analogous approach has been previously and successfully applied to 
study cell heterogeneity during in vivo CD8 T-cell differentiation (12, 13). Recently, 
single cell gene expression profiling was shown to allow identifying qualitative 
differences in CD8 T-cell responses elicited by different gene-based vaccines (14).  
We found that anti-tumor T-cell function was primarily determined by the type of 
peptide used for vaccination (native versus analog) and was not inherent to the degree 
of prevalence of a given T-cell clonotype (dominant versus non-dominant). 
Moreover, similar distributions in memory/effector gene expression signatures were 
found between T-cell clonotypes issued from the same subset of differentiation. 
Comparable observations were made for EBV- and CMV-specific T-cells, indicating 
that the functional profile of individual T-cells is also influenced by the 
differentiation status. As a consequence, most if not all clonotypes from a given 
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subset of differentiation and participating in a tumor (self) or viral (non-self) T-cell 
response may be equally competent. Selection of a T-cell repertoire composed of 
low/non-dominant and dominant clonotypes could serve to promote clonotypic 
diversity, while maintaining functional competence. These results are consistent with 
the report by Messaoudi and colleagues (15) that a diverse TCR repertoire but not a 
restricted one can mobilize protective antigen-specific T-cells of high avidity and 
efficient target cell killing.  
Our data also show that a synthetic vaccine (i.e. decapeptide, CpG-ODN and IFA (9)) 
was able to trigger a similar composition of T-cell clonotypes as in viral infections (5, 
7), and particularly in EBV-specific T-cell responses (6). Responding T-cells were 
composed of clonotypes of varying frequencies (dominant, subdominant and non-
dominant), yet their clonal prevalence was dependent on the differentiation stage. 
Late-differentiated EM28- (“effector-like”) cells consisted primarily of patient-
specific dominant (high frequency) and subdominant (low frequency) clonotypes 
with long-term persistence. In contrast, the early-differentiated EM28+ subset (that 
includes “effector-memory” cells) contained mostly non-dominant clonotypes with 
only a small fraction of co-dominant T-cell clonotypes. Thus, clonotypic diversity 
was mostly found within the “effector-memory” EM28+ subset, whereas a selection 
was observed with advanced differentiation as certain clonotypes were enriched, 
while others were not. This process is likely clonotype-dependent, consistent with 
studies on T-cells specific for persistent viruses (5, 7), and highlighting the 
importance of the structural composition of the TCR repertoire for T-cell 
differentiation. Moreover, many tumor-specific clonotypes identified in the late-
differentiated “effector-like” subset were also found within the pool of less-
differentiated “effector-memory” cells, albeit at much lower frequencies. Co-
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existence of identical clonotypes as both “effector-memory” and “effector-like” T-
cells has also been described for human T-cells specific for influenza matrix protein 
peptide (16) and HIV epitopes (7). Together, these observations are in line with 
recent findings (17), showing that individual naive T-cells have multiple fates and 
can differentiate into both memory and effector T-cell subsets.  
Our single cell analysis confirmed that vaccination with native peptide was more 
efficient at inducing the expression of multiple effector molecules, and shows that 
this occurred in nearly all Melan-A-specific T-cell clonotypes. This correlated with 
efficient target cell killing. Consequently, both T-cell subsets (EM28+ and EM28-) 
induced by native-peptide vaccination closely resembled each other, and to the highly 
differentiated CMV-specific T-cells. These data refine our current view of the 
process of T-cell differentiation, as they indicate that progressive up-regulation of 
cytolytic activity does not necessarily require the stepwise loss of costimulatory 
(CD27, CD28) and cytokine receptor (IL-7Rα) expression. Previous reports have 
described a hierarchical order of T-cell differentiation stages, from naïve to CM, 
EM28+, EM28- and EMRA cells (12, 18-20). Specifically, it was shown that cellular 
differentiation (loss of CCR7/CD27/CD28 expression) was associated with 
progressive up-regulation of multiple “killer” mediators by the same cell (12). This 
report, together with our own observations (20), demonstrated tight correlations 
between particular cell surface markers (e.g. CCR7+/-, CD28+/-, and CD27+/-) and 
T-cell functional properties. While these studies were performed on circulating 
“bulk” CD8 T-cells irrespective of antigen-specificity, an alternative picture became 
apparent when assessing virus antigen-specific T-cells. Indeed, despite showing 
distinct expression patterns along with cell differentiation, CMV-specific cells also 
expressed globally higher levels of CD94, CD57, IFN-γ, perforin and granzyme B 
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than EBV-specific cells (6). The reasons behind this higher degree of differentiation 
and TCR clonotypic repertoire restriction are not fully understood. For example, it 
could be influenced by the differences in the biology of these viruses (21). 
Nevertheless, the fact that enhanced effector functions can be acquired without 
loosing expression of CD27, CD28 and IL-7Rα is likely important, since these 
receptors contribute significantly to memory cell function, essential for protection 
from disease. 
Unfortunately, it still remains unknown why the native peptide induced qualitatively 
better T-cell responses than the analog peptide. We still favor the hypothesis that the 
native peptide recruited T-cells with superior TCR affinity/avidity, selected to 
overcome the lower peptide binding to MHC (the analog peptide binds about 10 
times more stably to HLA-A2 than the native peptide (22)). Alternatively, 
vaccination with weak antigens may induce more profound T-cell activation through 
non-TCR mediated signals, e.g. enhanced co-stimulatory and/or reduced inhibitory 
pathways that are maintained in T-cell progeny. Therefore we are currently analyzing 
additional T-cell properties. Our preliminary data revealed relatively similar 
expression of the inhibitory receptors TIM-3, PD-1, CD160, CTLA-4 and BTLA 
among tumor-specific T-cells induced by native and analog peptide vaccination (Fig. 
S3 and S5).  
In the future, it will be important to clarify which of the observed properties are 
already present before vaccination. T-cells from healthy individuals should be 
analyzed in parallel, before and after vaccination. However, these are major 
challenges, since clinical studies in healthy individuals are difficult to conduct. 
Furthermore, the frequencies of tumor-specific T-cells are very low in non-vaccinated 
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individuals, or after vaccination without CpG-ODN, even in melanoma patients, thus 
severely limiting direct ex vivo analysis. 
We conclude that non-dominant clonotypes may display similar functions as their 
dominant counterparts, both for tumor- and virus-specific T-cells. High-resolution 
characterization of individual T-cells at the clonotype level provides the basis to 
identify the biological benchmarks associated with protective T-cell immunity, 
contributing to the rational development of vaccines.  
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MATERIALS AND METHODS 
Patients and healthy blood donors. Fifteen HLA-A*0201-positive patients with 
stage III/IV metastatic melanoma were included in a phase I prospective trial of the 
Ludwig Institute for Cancer Research and the Multidisciplinary Oncology Center, 
approved by institutional review boards and regulatory agencies (9, 10). Patients 
received monthly low-dose vaccinations injected subcutaneously with 100 µg of 
either the Melan-AMART-126-35 unmodified native peptide (EAAGIGILTV) or the 
Melan-AMART-126-35 analog A27L peptide (ELAGIGILTV), mixed with 0.5 mg CpG-
ODN 7909 / PF-3512676 (Pfizer and Coley Pharmaceutical Group) and emulsified in 
Incomplete Freund’s Adjuvant (IFA) (Montanide ISA-51; Seppic) (9). Leukapheresis 
from two healthy donors (BCL6 and BCL8) with positive EBV- and CMV-specific 
CD8 T-cell responses were collected upon informed consent.  
 
Cell preparation and flow cytometry. Samples were collected and processed as 
described in the SI Text. Purified CD8 T-cells were stained with HLA-A2/peptide 
multimers and then with appropriate mAbs, and sorted into defined sub-populations 
on a FACSVantage SE or a FACSAria (BD Biosciences, San Diego, CA) or 
immediately analyzed on a LSR IITM flow cytometer (BD Biosciences), using 
CellQuest (BD Biosciences) or FlowJo (TreeStar) software. 
 
Generation of T-cell clones and functional cytolytic assays. HLA-A2/multimer+ 
CD8+ T-cell subsets (EM28+, EM28-, and EMRA) were sorted by flow cytometry, 
cloned by limiting dilution, and expanded as described in the SI Text. Tumor cell 
killing and efficiency of antigen recognition by in vitro generated T-cell clones was 
analyzed as detailed in the SI Text.  
 18 
    
cDNA preparation, gene expression and TCR BV analysis. cDNA preparation, 
cDNA amplification and PCR were performed on individually sorted single-cell 
samples as described in the SI Text. 105 cells from T-cell clones were processed 
through direct lysis and cDNA synthesis without undergoing the global cDNA 
amplification procedure. Specific PCR reactions and TCR BV CDR3 spectratyping, 
sequencing and clonotyping were performed as detailed in the SI Text. The term 
“dominant clonotype” refers to a nucleotide sequence found at least twice in a given 
patient and time-point (> 1% of frequency) (23). 
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FIGURE LEGENDS 
Figure 1. Analysis of TCR BV repertoire diversity and quantification of tumor-
specific T-cell clonotypes. A, Ex vivo analysis of circulating Melan-A26-35 specific 
CD8+ T-cells over time in fifteen melanoma patients vaccinated with either the 
analog A27L-modified (n = 10) or the unmodified native (n = 5) peptide, combined 
with CpG-ODN and IFA. Data are expressed as percentages of CD28- Melan-A-
specific T-cells. B, cDNA pools (50-100 cells), ex vivo sorted from peripheral blood 
following vaccination with native or analog peptide, were amplified by PCR using 22 
BV-specific primers, and subjected to electrophoresis. TCR BV repertoire diversity is 
expressed as the total number of amplified BV-CDR3-BC products of different 
lengths within each positive BV family. C, Distribution of dominant and non-
dominant T-cell clonotypes within EM28+ and EM28-/EMRA T-cell subsets. 
Compiled data representing mean clonotypic frequencies of Melan-A specific T-cells 
after vaccination with the analog (n = 4 patients) or native (n = 4) peptide and T-cells 
specific for EBV (n = 3 healthy donors) and CMV (n = 3). Analyses were performed 
on large numbers of in vitro generated T-cell clones (n = 1487). Dominant clonotypes 
are defined as high (≥ 10%) or low (1-9%), while non-dominant T-cell clonotypes as 
< 1% of epitope-specific T-cells. * 0.01 < P < 0.05, *** P < 0.005 (two-tailed 
unpaired t test).  
 
Figure 2. Ex vivo gene expression profiling of individually sorted T-cells. A, Gene 
expression analysis was performed on cDNA obtained from individually sorted 
single-cell samples isolated from EM28+ and EM28- T-cell subsets (patients 
vaccinated with analog or native peptide), and from EM28+ and EMRA subsets 
(EBV- and CMV-specific T-cells from the healthy individual BCL8). Positive PCR 
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products are depicted in red, negative ones in blue. Compiled data are shown per 
subset and per patient/healthy individual, where each line represents an individual T-
cell. B, Complete sets of data of the proportion of each expressed gene in early- 
(EM28+) or late- (EM28-/EMRA) differentiated subsets from four patients 
vaccinated with analog (LAU 618, ; LAU 672, ) and native peptide (LAU 1013, 
; LAU 972, ), and from two healthy donors BCL8 (EBV,; CMV, ) and 
BCL6 (CMV, ). C, A hierarchical clustering (left panel) (n = 529 single-cell 
samples) was performed based on Euclidean distance between samples with the 
UPGMA clustering method (as described in SI Text) and allowed the identification of 
5 distinct clusters. The repartition of these clusters within the single-cell samples of 
each EM28+ and EM28- T-cell subset (specific for ELA, EAA, EBV or CMV) was 
determined by Heat-map analysis (right panel).  
 
Figure 3. Ex vivo expression of effector proteins within tumor- and virus-specific 
CD8 T-cell subsets by multi-parameter flow cytometry. The proportion of CD57, 
perforin and granzyme B protein expression was determined within antigen-specific 
EM28+ and EM28- T-cell subsets from fifteen melanoma patients following analog 
(ELA, n = 10) or native (EAA, n= 5) peptide vaccination, and from seven healthy 
individuals with EBV (n= 5) and/or CMV (n = 5) specific T-cell responses. * 0.01 < 
P < 0.05, ** 0.005 < P < 0.01, *** P < 0.005 (two-tailed unpaired t test). 
 
Figure 4. Co-expression of effector molecules by T-cell clonotypes. Poly-functional 
gene expression profile was determined for dominant (A) and non-dominant (B) 
tumor- and virus-specific T-cell clonotypes, upon ex vivo single-cell sorting of 
EM28+ and EM28-/EMRA T-cells. Dominant clonotypes (A) are defined according 
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to their relative frequencies in epitope specific T-cell subsets as high (> 10 %) or 
intermediate (1-9 %), and non-dominant TCRs (B) as frequencies < 1%. The pie 
charts illustrate co-expression of CD94, IFN-γ, perforin and granzyme B as detected 
in single-cell samples from four patients vaccinated with the analog (n = 2) and the 
native (n = 2) peptide and two healthy individuals. 
 
Figure 5. Tumor cell killing and efficiency of antigen recognition. Tumor-specific T-
cell clones were in vitro generated from four patients following analog (n = 2) or 
native (n = 2) peptide vaccination. A, Tumor reactivity for melanoma cell lines 
Me290 (A2+/Melan-A+) and NA8 (A2+/Melan-A-) in the absence or presence of 
synthetic Melan-A analog peptide (1 µM), at an effector:target ratio of 30:1. Each 
line represents an individual clone derived from EM28+ and EM28- subsets after 
analog (n = 153) or native (n = 80) peptide vaccination. B, Complete set of data 
representing specific lysis of the Melan-A+ Me290 tumor cell line without exogenous 
peptide (effector:target ratio; 10:1) by T-cell clones derived from EM28+ and EM28- 
subsets following analog (n = 2 patients; grey whiskers) or native (n = 2; empty 
whiskers) peptide vaccination. To allow direct comparison, clones were divided into 
dominant (frequencies > 1%) and non-dominant (frequencies < 1%) subgroups. ** 
0.0001 < P < 0.001, *** P < 0.0001 (two-tailed unpaired t test). 
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SUPPORTING MATERIAL AND METHODS 
 
Patients. HLA-A2-positive patients with histological proven metastatic (stage III/IV) 
melanoma expressing Melan-A (RT-PCR or immuno-histochemistry) were included upon 
written informed consent, as described previously (1, 2). The following inclusion criteria 
had to be fulfilled: Karnofsky performance status of 70%, normal CBC and kidney-liver 
function, no concomitant anti-tumor therapy nor immunosuppressive drugs. Exclusion 
criteria were pregnancy, seropositivity for HIV-1 Ab or HBs Ag, brain metastases, 
uncontrolled bleeding, clinically significant autoimmune disease, and symptomatic heart 
disease (NYHA III-IV). Study end points were toxicity and CD8 T-cell responses. 
 
Cell preparation, antibodies, and flow cytometry. Ficoll-Paque centrifuged peripheral 
blood mononuclear cells (PBMCs) were cryopreserved in RPMI 1640, 40% FCS and 
10% DMSO. Synthesis of phycoerythrin (PE)-labeled HLA-A*0201/peptide multimers 
with A27L Melan-AMART-126-35 (ELAGIGILTV), EBV BMLF1280-288 (GLCTLVAML), 
and CMV pp65495-503 (NLVPMVATV) was prepared as described previously (3). Before 
staining, CD8pos T-cells were positively enriched using a MiniMACS device (Miltenyi 
Biotech, Bergish Gladbach, Germany) resulting in > 90% CD3posCD8pos cells. Cells were 
stained in PBS, 0.2% BSA, 50 µM EDTA with multimers (1 µg/ml, 60 min, 4°C), and 
sorted into defined sub-populations on a FACSVantage SE or a FACSAria (BD 
Biosciences, San Diego, CA) or immediately analyzed on a LSR IITM flow cytometer 
(BD Biosciences), using CellQuest (BD Biosciences) or FlowJoTM (TreeStar) software. 
For dead cell exclusion, cells were stained with Live/Dead Fixable Dead Cell violet stain 
(Molecular Probes / Invitrogen). Extracellular and intracellular stainings were performed 
according to the manufacturer’s instructions. Manipulations were done at 4oC, avoiding 
gene expression alteration due to staining and sorting procedures.  
All flow cytometry-based sorting experiments (ex vivo single-cell aliquots, and in vitro 
generation of T-cell clones) were performed using the following 5-color stain 
combination: (a) PE-HLA-A2/peptide multimers, (b) FITC-conjugated anti-CD28 (BD 
Biosciences), (c) PE-Texas Red-conjugated anti-CD45RA (Beckman Coulter), (d) APC-
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Cy7-conjugated anti-CD8 (BD Biosciences) reagents and (e) anti-CCR7 mAb (BD 
Biosciences) followed by APC-conjugated goat anti-rat IgG Ab (for indirect staining for 
CCR7) (Caltag Laboratories).  
Multi-parameter flow cytometry analyses were performed using the following 8-color 
stain strategy: (a) PE-HLA-A2/peptide multimers, (b) FITC-conjugated anti-CD57 (BD 
Biosciences) or -PD1 (BD Biosciences) or -Granzyme B (Hölzer Diagnostic) or –Perforin 
(Ancell), (c) PE-Texas Red-conjugated anti-CD45RA (Beckman Coulter), (d) PE-Cy7-
conjugated CCR7 (BD Biosciences), (e) Alexafluor700 anti-CD28 (Biolegend), (f) 
Pacific Blue-labeled anti-CD8, (g) PerCP-Cy5.5 anti-CD127 (IL-7R) (Beckman Coulter), 
and (h) APC-eFluor780-conjugated anti-CD27 (eBioscience) mAbs. 
For antibody staining of inhibitory receptors, samples were purified and enriched for 
CD8pos T-cells, and then stained using Melan-AMART-1 multimers as described above. 
Melan-A-specific multimers were labeled with APC-eFluor 780 (eBioscience) and after 
45 min at 4oC, cells were washed and surface staining was performed for CD8, CCR7, 
CD45RA, and (a) 2B4 (PE-Cy5.5; BioLegend) and BTLA (PE; BD Biosciences) or (b) 
KLRG-1 (Alexa Fluor 488; a gift from H.-P. Pircher, Department of Immunology, 
University of Freiburg, Freiburg, Germany), TIM-3 (PE; R&D Systems), and CD160 
(Alexa Fluor 647; eBioscience) as described elsewhere (4). Samples (a) were fixed at 
room temperature for 30 min (1% formaldehyde buffer) and then stained for CTLA-4 
(APC; BD Biosciences) in FACS buffer for 0.1% saponin for 30 min at 4oC. Live/Dead 
Fixable Aqua (Invitrogen) was used as dead cell exclusion marker, and appropriate 
isotype controls were used to define negative populations. Data were acquired on a 
GalliosTM Flow Cytometer (Beckman Coulter) analyzed using FlowJoTM (TreeStar).  
For intracellular cytokine (IFN-γ) and degranulation (CD107a/LAMP1) analyses, cells 
were kept overnight in RPMI 10% FCS at 37oC and 5% CO2. CD8pos T-cells were 
enriched as described above, and purified CD8pos T-cells were first pre-stained with PE-
labeled multimers for 30 min at 4oC.  4x105 T-cells were incubated with 2x105 T2 cells at 
37°C for 4h with or without 10 μM peptide (Melan-A/MART-1 ELAGIGILTV) and anti-
CD107aFITC (BD Biosciences), whereby 10 μg/ml Brefeldin A (Sigma, St. Louis, MO) 
was added for the last 3h, in culture medium consisting of RPMI supplemented with 0.55 
mM Arg, 0.24 mM Asn, 1.5 mM Gln, and 8 % pooled human Apos serum. Subsequently, 
cells were stained at 4°C with PE-labeled multimers, anti-CD8, anti-CD28 and anti-
CD45RA antibodies. For dead cell exclusion, cells were stained with Live/Dead Fixable 
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Dead Cell violet stain (Invitrogen). Then, cells were permeabilized with 0.1 % saponin at 
4°C, washed, and stained for 40 min with anti-IFNγPe-Cy7 (BD Biosciences). CD8pos T-
cells were acquired with a flow cytometry LSR IITM machine, and analyzed with 
FlowJoTM software (TreeStar). Data are indicated in percentages of circulating CD8pos T-
cells.  
 
Generation of T-cell clones. HLA-A2/multimerpos CD8pos T-cell subsets (EM28pos, 
EM28neg, and EMRA) were sorted by flow cytometry, cloned by limiting dilution and 
expanded in RPMI 1640 medium supplemented with 8% human serum, 150 U/ml 
recombinant human IL-2 (rhIL-2; a gift from GlaxoSmithKline), 1 µg/ml 
phytohemagglutinin (PHA; Sodiag, Losone, Switzerland) and 1 × 106/ml irradiated 
allogeneic PBMC (3000 rad) as feeder cells. T-cell clones were expanded by periodic 
(every 15 days) restimulation with PHA, irradiated feeder cells, and rhIL-2. 
 
Direct cell lysis and cDNA synthesis. Single-cell or five-cell aliquots were sorted by 
flow cytometry directly into 96-V bottom plates containing 15 µl of a lysis/cDNA mix 
solution supplemented with 1.2% Triton X-100 (Fluka), 30 µg/ml tRNA (Roche), 10 mM 
DTT (Fluka), 0.5 mM dNTP (Invitrogen, Paisley, UK), 2 ng/µl of a 20-mer oligo-dT 
(Amplimmun, Madulain, Switzerland), 4 U of RNAsin (Promega, Madison, WI), 3 µl of 
RT buffer (5x; Invitrogen) and 40 U of M-MLV transcriptase (Invitrogen), as described 
in detail elsewhere (5). To allow the transcription of total mRNA into cDNA, the 96-well 
plates were incubated 60 min at 37oC, briefly centrifuged and transferred into 0.5 ml PCR 
tubes. MMLV-RT transcriptase was inactivated at 90oC for 3 min and samples were 
stored at -80oC until further use. For T-cell clones, 15 µl of lysis/cDNA mix was directly 
added to 105 cells and further processed as described above. 
 
Global cDNA amplification from single-cells. The basic principle of the five-cell and 
single-cell global cDNA amplification protocol requires that the target sequences to be 
amplified be flanked by known sequences to which the amplification primers can anneal 
and initiate polymerization. One end is initially defined through a cDNA reaction using 
reverse transcriptase and an oligo(dT) primer that will prime via the poly(A) tail present 
at the 3’ end of most mRNA molecules. The other end is then created by the addition of 
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an homopolymer d(A) sequence to the 3’-OH end of the first cDNA using terminal 
deoxynucleotidyl transferase. Global PCR amplification of the dA/dT flanked cDNAs is 
carried out using a single modified oligo(dT) primer as previously described by Brady 
and Iscove (6). Priming of the cDNA during global RT-PCR is initiated via annealing of 
the d(T) region of the 61-mer oligonucleotide primer to the homopolymeric d(A) regions 
present at the termini of the cDNA molecules. We have included a purification step 
before adding the poly d(A) tails, in order to get rid of free dNTPs that may interfere 
during the tailing reaction. Therefore, for further processing, cDNA from single-cell or 
five-cell aliquots were precipitated overnight at -20oC after addition of 7.5 µl of 
C2H7NO2 7.5 M (Fluka), 45 µl of ethanol 100% (Fluka) using 2 µl of Glycogen 10 mM 
(Roche) as carrier, washed in 150 µl of cold ethanol 70% and dried 1 hour at room 
temperature.  
To evaluate mRNA expression in small numbers of cells (single or five-cell sorted 
samples), the following method was adapted from previously published protocols (6, 7). 
Briefly, to allow 3’oligo(dA) tailing to cDNA, the dried pellets were suspended in 5 µl of 
tailing solution containing 0.5 mM dATP (Amersham Pharmacia), 1 U of Terminal 
deoxynucleotidyl Transferase (Promega) and 1 µl tailing buffer (5x; Promega) and 
incubated at 37oC for 30 min. After denaturation (94oC for 3 min), 45 µl of PCR-buffer 
(10 mM Tris-HCl pH 8.8, 50 mM KCl, 0.1 mg/ml BSA, 2 mM MgCl2) containing 20 
ng/µl of a 61-mer oligo dT (5’-CATGTCGTCCAGGCCGCTCTGGGACAAAATATG 
AATTCT23-3’) (Metabion), 0.2 mM dNTP, 0.5% Triton X-100, and 5 U Taq DNA 
recombinant polymerase Platinum (Invitrogen) were added, followed by 5 cycles of PCR 
(50s at 94oC; 2 min at 37oC; 9 min at 72oC) and of 35 cycles (50s at 94oC; 90s at 60oC; 8 
min at 72oC). 1 µl of amplified cDNA (also defined as cDNAplus) was then subjected to a 
second round of PCR amplification (38-40 cycles, 30s at 94oC; 45s at 58oC; 1 min at 
72oC) in 20 µl volumes of 1x PCR buffer containing 1.5 mM MgCl2, 0.2 mM dNTP, 0.5 
U Taq Platinum and 40 ng of specific primers designed to amplify mRNA sequences of 
interest and the expected products were visualized after electrophoresis on a 1.2% 
agarose gel. Typically, we used H20 for the negative PCR control, while 103 PBMCs 
from a healthy individual were used as positive PCR control. 
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Gene expression analysis. For gene expression analysis of single cells, we used the 
following primers: CD3: 5’-CGTTCAGTTCCCTCCTTTTCTT-3’; rev-5’-
GATTAGGGGGTTGGTAGGGAGT G-3’, GAPDH: 5’- GGACCTGACCTGCCGTC 
TAG-3’; rev-5’-CCACCACCCTGTTGCTGTAG-3’, CCR7: 5’-CCAGGCCTTATCTCC 
AAGACC-3’; rev-5’-GCATGTCATCCCCACTCTG-3’, CD27: 5’-ACGTGACAGAGT 
GCCTTTTCG-3’; rev-5’-TTTGCCCGTCTTGTAGCATG-3’, CD127/IL-7Ra: 5’-ATC 
TTGGCCTGTGTGTTATGG-3’; rev-5’-ATTCTTCTAGTTGCTGAGGAAACG-3’; 
CD94: 5’-GTGGGAGAATGGCTCTGCAC-3’; rev-5’-TGAGCTGTTGCTTACAGA 
TATAACGA-3’, IFN-γ: 5’-GCCAACCTAAGCAAGATCCCA-3’; rev-5’-GGAAGC 
ACCAGGCATGAAATC-3’, Perforin: 5’-TT CACTGCCACGGATGCCTAT-3’; rev-5’-
GCGGAATTTTAGGTGGCCA-3’, Granz B: 5’-GCAGGAAGATCGAAAGTGCGA-3’; 
rev-5’-GCATGCCATTGTTTCGTCCAT-3’. All ex vivo single-cell cDNA samples were processed with the same rigorous approach to allow direct comparison among individuals and subsets. 
 
TCR spectratyping, sequencing and clonotyping. To rapidly identify TCR Vβ segment 
usage, a small fraction (5 µl of a total of 50 µl) from 10 individually sorted and amplified 
5-cell cDNA samples were pooled and subjected to individual PCR in non-saturating 
conditions using a set of previously validated fluorescent-labeled forward primers 
specific for the 22 TCR Vβ subfamilies and one unlabeled reverse primer specific for the 
corresponding C gene segment (8, 9). This TCR Vβ-CDR3 spectratyping analysis based 
on the equivalent of 50 cells represents a pre-screening step. Once positive TCR Vβ 
subfamilies were identified, the following step consisted in subjecting each individually 
generated single-cell or five-cell cDNA sample, and in parallel in vitro generated T-cell 
clone to TCR Vβ PCRs. Separation and detection of amplified fragments that contain the 
entire CDR3 segment was performed in the presence of fluorescent size markers on an 
ABI PRISM 310 Genetic Analyzer (AppliedBiosystems, Rotkreuz, Switzerland) 
according to the manufacturer’s recommendations, and data were analyzed with 
GeneScan 3.7.1 (AppliedBiosystems). In the last step, PCR products of interest were 
directly purified and sequenced from the reverse primer (Fasteris SA, Plan-les-Ouates, 
Switzerland). Clonotypic primers for several CDR3 sequences were validated and used in 
clonotypic PCR for determination of clonotype frequencies as previously reported (10, 
11). All ex vivo single-cell or in vitro T-cell clone cDNA samples were processed with 
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the same rigorous approach to allow direct comparison among individuals and subsets. 
 
Hierarchical clustering analyses. Hierarchical agglomerative clustering and dendrogram display of gene expression data were performed with HCE (Hierarchical Clustering Explorer) version 3.5 (http://www.cs.umd.edu/hcil/hce/). All PCR results were encoded into a data matrix in which the assigned value was +1 for a positive PCR product and 0 for a negative PCR product. The data were examined without normalization/transformation using Euclidean distance with the Unweighted Pair Group Mean Arithmetic (UPGMA) clustering method. The cluster 
dendrogram identified 5 distinct clusters (minimum similarity set to 0.375). Control genes (GAPDH and CCR7) were not included during clustering analysis. 
 
Chromium release and tumor recognition assays. Lytic activity and antigen 
recognition was assessed functionally in 4-h 51Cr-release assays using T2 target cells 
(HLA-A*0201+/Melan-A-) pulsed with serial dilutions of the native Melan-AMART-126-35 
peptide (EAAGIGILTV) or of the analog Melan-AMART-126-35 A27L (ELAGIGILTV) 
(12). The percentage of specific lysis was calculated as 100 × (experimental − 
spontaneous release)/(total − spontaneous release). Similarly, the specific antigen 
recognition lytic activity of the Melan-AMART-1-specific T-cell clonotypes was assessed 
against the melanoma cell lines NA8 (HLA-A2+/Melan-A-) and Me 290 (HLA-
A2+/Melan-A+) in the presence or absence of the indicated peptide at the indicated 
concentration. 
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SUPPORTING FIGURE LEGENDS 
Figure S1. (A) Analysis of relative frequencies of public T-cell clonotypes within Melan-
A-specific T-cells. Graphs summarize the distribution of the public amino acid TCR β-
domain sequences detected in fifteen melanoma patients vaccinated either with the analog 
(n = 10) or the native (n = 5) peptide vaccine, according to their relative frequency. Non-
dominant clonotypes (< 1% of tumor-specific T-cells) are represented in white, low 
dominant (1-9%) are in gray, and high dominant (with frequency > 9%) are in black.  
These public TCR BV sequences were equivalently distributed within the two cohorts of 
vaccinated patients. The majority of these TCR BV public sequences were largely present 
as non-dominant or as low dominant sequences in individual patients (> 90%), but they 
were recurrent as they are found in various patients. Importantly, only a minority of 
public clonotypes (between 3 to 6 %) was typically found at higher frequencies (also 
defined as dominant clonotypes). Altogether, these data indicate that public T-cell 
clonotypes are rather infrequent within Melan-A-specific T-cell responses of both cohorts 
of patients (analog and native peptide vaccination). In contrast, the dominant tumor-
specific T-cell clonotypes of high frequency that expand during peptide vaccination are 
highly specific to individual patients as defined by their private CDR3β sequences. (B) 
Analysis of the T-cell clonotype repertoire following sorting with multimers constructed 
with analog versus native peptide. Clonotypic PCR was performed on in vitro generated 
specific T-cell clones from patients LAU 618 (n = 511 clones) and LAU 972 (n = 246 
clones), vaccinated respectively with the analog or the native peptide. Each dominant 
clonotype (frequency ≥ 1%) is indicated and each TCR BV family is color-coded. Non-
dominant clonotypes are designed as “BV other” and are comprised of clonotypes of 
unique TCR BV/CDR3 sizes and/or BV-CDR3-BC sequences as determined by capillary 
electrophoresis and sequencing. The frequencies/proportions of T-cell clonotypes within 
early-differentiated EM28pos and late-differentiated EM28neg T-cell subsets sorted using 
the analog peptide multimers is directly compared with those obtained following native 
peptide multimer sorting. TCR BV usage and sequences were described according to the 
Arden nomenclature (13). The tumor-specific TCR repertoire contained similar frequencies of dominant and non-dominant T-cell clonotypes following sorting with both multimers, thus showing a very high degree of cross-reactivity and indicating that the two multimers efficiently bound to all Melan-A-specific T-cells with similar fine specificity to analog or native peptide, in line with our previous report (2). 
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Figure S2. Ex vivo gene expression analysis of effector mediators in individually sorted 
Melan-A-specific T-cell subsets. (A) Examples of gene expression profiles in two 
patients vaccinated with the analog (LAU 672) or the native (LAU 972) peptide. Primers 
designed for GAPDH, CCR7, CD27, IL-7Rα, CD94, IFN-γ, perforin and granzyme B 
mRNA transcripts are depicted. Data from 15 independent single-cell aliquots are shown. 
(B) The pie charts depict co-expression profiles of CD94, IFN-γ, perforin and granzyme 
B within individually single-cell samples from (i) tumor-specific EM28pos and EM28neg 
T-cell subsets (four melanoma patients) and (ii) virus-specific EM28pos and EM T-cell 
subsets (two healthy donors) as described in the main manuscript. Patients vaccinated 
with the analog peptide are LAU 618 and LAU 672, whereas patients vaccinated with the 
native peptide are LAU 1013 and LAU 972. EBV-specific T-cell responses were 
characterized from healthy donor BCL8 and CMV-specific responses from healthy 
individuals BCL6 and BCL8.   
 
Figure S3. Ex vivo expression of effector mediators in antigen-specific CD8 T-cell 
subsets by multi-parameter flow cytometry. (A) The proportion of CD57, perforin and 
granzyme B protein expression among antigen-specific EM28+ and EM28- subsets was 
determined by multi-parameter flow cytometry. The dotted line was set according to the 
gating obtained on bulk CD8+ naive T-cells known to be CD57-perforin-granzymeB-. 
Representative examples are shown. (B) The proportion of CD27, IL-7Rα and PD1 
protein expression was determined within EM28pos and EM28neg T-cell subsets from 
fifteen melanoma patients following analog (ELA, n = 10; grey whiskers) or native 
(EAA, n= 5; white whiskers) peptide vaccination, and from seven healthy individuals 
with EBV (n= 5; dashed grey whiskers) and/or CMV (n = 5; dashed white whiskers) 
specific T-cells. (C) Direct ex vivo analysis of tetramer-gated T-cells for cytokine 
production (IFNγ) and degranulation (CD107a/LAMP-1), after 4h incubation with 
peptide-pulsed T2 cells as described in the Supporting Material and Methods. Data were 
obtained from melanoma patients vaccinated with the analog/ELA (n = 8) and the 
native/EAA (n = 4) peptide. The analysis included the two subpopulations CD28pos and 
CD28neg cells. Of note, the production of IFNγ and up-regulation of LAMP-1/CD107a by 
tumor (Melan-A) specific T-cells were similar between both cohorts of patients (with no 
statistically significant differences as assessed by two-tailed unpaired t test).  
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Figure S4. Functional avidity was assessed using T2 target cells (A2pos/TAPneg/neg) pulsed 
with graded concentrations of analog/ELA Melan-A26-35 peptide. Tumor-specific T-cell 
clones were in vitro generated from four melanoma patients following analog (n = 2) and 
native (n = 2) peptide vaccination as described in Supporting Material and Methods. 
Complete set of data representing maximal lysis (A) and EC50 (e.g. peptide concentration 
required to achieve 50% of maximal lysis) (B). Clones with undetectable lytic activity 
(EC50 > 10-6 M and/or maximal lysis < 20%) are symbolized as single dots and were not 
included in the statistical evaluations. * 0.001 < P < 0.01, ** 0.0001 < P < 0.001, *** P < 
0.0001 (two-tailed unpaired t test). (A, B) To allow direct comparison, clones were 
divided into dominant (frequencies > 1%) and non-dominant (frequencies < 1%) 
subgroups. Native peptide vaccination-induced T-cells derived from EM28pos cells were 
again significantly superior in regards to maximal lysis capacity, compared to the killing 
responses obtained from the corresponding subset upon analog peptide vaccination. 
Efficient maximal T2 lysis was found for both dominant and non-dominant clonotypes 
issued from native peptide vaccination, as well as from the EM28neg subsets. Regarding 
functional avidity (EC50), all native and analog peptide-derived EM28pos T-cell clones 
behaved similarly, with 50% maximal lysis of T2 cells found at comparable peptide doses 
(and no statistically significant differences). Yet, T-cell clones derived following analog 
peptide vaccination showed a higher degree of heterogeneity where a substantial fraction 
of the clones depicted poor to no killing, contrasting with the native peptide vaccination-
induced clones displaying more homogeneous killing capacities.  
 
Figure S5. Ex vivo multimer staining assessing expression of inhibitory receptors. Tumor 
(Melan-AMART-1) specific T-cells were analyzed for the expression of 5 different 
inhibitory receptors; TIM-3, KLRG-1, BTLA, CTLA-4 and CD160 as well as the 2B4 
receptor as recently described (4, 14). Analysis was performed on gated on CD8pos 
multimerpos T-cells from melanoma patients vaccinated either with the analog/ELA (n = 6 
patients) or the native/EAA (n = 3 to 4 patients) peptide. Of note, even though many 
tumor-specific T-cells can express inhibitory receptors such as TIM-3, KLRG-1 and 
BTLA, they nevertheless also maintain functional competence (i.e. by expressing IFN-γ, 
perforin and granzyme B mediators and retaining killing capacities as shown in the main 
manuscript). In line with these observations, we recently described that while tumor-
specific T-cells found within peripheral blood from melanoma patients can acquire 
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substantial effector cell properties, they display an exhaustion profile within metastatic 
lesions (4). Finally, no differential expression of inhibitory receptors was found within 
tumor-specific T-cells derived from patients vaccinated with the analog versus the native 
peptide. 
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Table S1. Clinical characteristics of patients 
Patient Gender 
Age at 
diagnosis 
(years) 
Disease stage at 
diagnosis  Type of vaccine
1 # of vaccines 
Duration2 
(mo) 
Clinical 
outcome 
LAU 205 M 24 pT2aN1M0 ELA+IFA+CpG 20 22.4 † 
LAU 321 M 60 pT3aN0M0,IIa ELA+IFA+CpG 8 7.5   
LAU 371 F 30 pT3aN1M0,III ELA+IFA+CpG 6 6.1 † 
LAU 444 F 28 pT3aN0M0 ELA+IFA+CpG 20 21.9 † 
LAU 618 F 70 pT4N0M0 ELA+IFA+CpG 12 11.9   
LAU 672 M 35 pT1N0M0 ELA+IFA+CpG 4 2.8 † 
LAU 818 M 55 pT3bN0M0,IIb ELA+IFA+CpG 18 20.5   
LAU 936 F 52 pT3aN0M0,IIa ELA+IFA+CpG 7 7.0 † 
LAU 944 F 20 pT1aN0M0 ELA+IFA+CpG 16 16.3   
LAU 1164 M 52 pTxNxM1a ELA+IFA+CpG 14 36.0   
LAU 972 F 60 pT2bN1M0 EAA+IFA+CpG 20 21.5   
LAU 975 M 52 pT4N1bM0 EAA+IFA+CpG 4 2.9 † 
LAU 1013 M 56 pT3bN3M0 EAA+IFA+CpG 8 8.4 † 
LAU 1015 M 75 pT2aN0M1a,IV EAA+IFA+CpG 20 22.4 † 
LAU 1106 M 36 pT2aN1M0,IIIa EAA+IFA+CpG 27 44.8   
1 ELA refers to the analog Melan-A/MART-1 peptide and EAA to the native unmodified peptide 
2 Time (months) during which the patient received monthly vaccinations 
† Death 
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